JP2003520246A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003520246A5 JP2003520246A5 JP2001552925A JP2001552925A JP2003520246A5 JP 2003520246 A5 JP2003520246 A5 JP 2003520246A5 JP 2001552925 A JP2001552925 A JP 2001552925A JP 2001552925 A JP2001552925 A JP 2001552925A JP 2003520246 A5 JP2003520246 A5 JP 2003520246A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- cop1
- medicament
- cns
- injury
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101100273635 Rattus norvegicus Ccn5 gene Proteins 0.000 description 11
- 210000003169 central nervous system Anatomy 0.000 description 10
- 208000014674 injury Diseases 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 210000001428 peripheral nervous system Anatomy 0.000 description 6
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 239000004472 Lysine Substances 0.000 description 5
- 235000004279 alanine Nutrition 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000013922 glutamic acid Nutrition 0.000 description 5
- 235000018977 lysine Nutrition 0.000 description 5
- 235000002374 tyrosine Nutrition 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
- 239000004220 glutamic acid Substances 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 229920005604 random copolymer Polymers 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000018652 Closed Head injury Diseases 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000047918 Myelin Basic Human genes 0.000 description 1
- 101710107068 Myelin basic protein Proteins 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 150000002307 glutamic acids Chemical class 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48779300A | 2000-01-20 | 2000-01-20 | |
| US09/487,793 | 2000-01-20 | ||
| US20979900P | 2000-06-07 | 2000-06-07 | |
| US06/209,799 | 2000-06-07 | ||
| US62021600A | 2000-07-20 | 2000-07-20 | |
| US09/620,216 | 2000-07-20 | ||
| PCT/US2001/002117 WO2001052878A2 (en) | 2000-01-20 | 2001-01-22 | The use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003520246A JP2003520246A (ja) | 2003-07-02 |
| JP2003520246A5 true JP2003520246A5 (enExample) | 2006-02-09 |
| JP4328050B2 JP4328050B2 (ja) | 2009-09-09 |
Family
ID=27395416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001552925A Expired - Fee Related JP4328050B2 (ja) | 2000-01-20 | 2001-01-22 | 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6844314B2 (enExample) |
| EP (1) | EP1248643B1 (enExample) |
| JP (1) | JP4328050B2 (enExample) |
| KR (1) | KR100822695B1 (enExample) |
| CN (1) | CN100360180C (enExample) |
| AT (1) | ATE302020T1 (enExample) |
| AU (1) | AU780188B2 (enExample) |
| CA (1) | CA2397785C (enExample) |
| DE (1) | DE60112718T2 (enExample) |
| DK (1) | DK1248643T3 (enExample) |
| ES (1) | ES2243450T3 (enExample) |
| HK (1) | HK1054507B (enExample) |
| IL (2) | IL150800A0 (enExample) |
| MX (1) | MXPA02007106A (enExample) |
| PT (1) | PT1248643E (enExample) |
| WO (1) | WO2001052878A2 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| IL141021A0 (en) | 1998-07-23 | 2002-02-10 | Yeda Res & Dev | Treatment of autoimmune conditions with copolymer 1 and related copolymers |
| ES2527760T3 (es) * | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| WO2000005249A2 (en) * | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| JP4328050B2 (ja) * | 2000-01-20 | 2009-09-09 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用 |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| HUP0302333A3 (en) * | 2000-06-05 | 2005-07-28 | Teva Pharma | The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| AU6887101A (en) * | 2000-06-20 | 2002-01-02 | Caprion Pharmaceuticals, Inc. | Copolymers and methods of treating prion-related diseases |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| US7429374B2 (en) | 2001-12-04 | 2008-09-30 | Teva Pharmaceutical Industries, Ltd. | Process for the measurement of the potency of glatiramer acetate |
| US7351686B2 (en) * | 2001-12-06 | 2008-04-01 | Yeda Research And Development Co. Ltd. | Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides |
| ES2386435T3 (es) * | 2003-01-07 | 2012-08-21 | Yeda Research And Development Co., Ltd. | Vacuna en forma de gotas oculares que contiene copolímero 1 para inmunización terapéutica |
| WO2005025596A1 (en) * | 2003-09-16 | 2005-03-24 | Hadasit Medical Research Services & Development Ltd. | Glatiramer acetate for use as an immuno-modulatory agent |
| JP5456235B2 (ja) | 2003-11-12 | 2014-03-26 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経変性疾患を治療するためのワクチン及び方法 |
| JP4808631B2 (ja) | 2003-12-09 | 2011-11-02 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 精神医学的障害の治療用のコポリマー１を含む方法及びワクチン |
| AU2005219876A1 (en) * | 2004-03-01 | 2005-09-15 | Peptimmune, Inc. | Methods and compositions for treatment of autoimmune diseases |
| EP1778286A4 (en) * | 2004-03-03 | 2009-04-08 | Teva Pharma | COMBINATION THERAPY WITH ACETATE OF GLATIRAMER AND RILUZOLE |
| JP5495490B2 (ja) | 2004-05-07 | 2014-05-21 | アレス トレーディング エスエイ | ランダム共重合体を用いる疾患の治療方法 |
| US7655221B2 (en) * | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| US20060194725A1 (en) * | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| CN101039691B (zh) * | 2004-06-25 | 2013-07-31 | 魁北克益得生物医学公司 | 用于治疗神经疾病的组合物和方法 |
| US20070269071A1 (en) * | 2004-08-10 | 2007-11-22 | 1...Limited | Non-Planar Transducer Arrays |
| HRP20160455T1 (hr) * | 2004-09-09 | 2016-07-15 | Yeda Research And Development Co., Ltd. | Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene |
| ZA200702591B (en) * | 2004-09-09 | 2009-03-25 | Teva Pharma | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
| AR052321A1 (es) * | 2004-10-29 | 2007-03-14 | Sandoz Ag | Procesos para la preparacion de un polipeptido |
| ES2541780T3 (es) * | 2004-11-29 | 2015-07-24 | Yeda Research And Development Co., Ltd. | Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1 |
| JP2008528589A (ja) * | 2005-02-02 | 2008-07-31 | テバ ファーマシューティカル インダストリーズ リミティド | 水素化分解を用いてポリペプチド混合物を作成する方法 |
| WO2006089164A1 (en) * | 2005-02-17 | 2006-08-24 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| CA2606194A1 (en) * | 2005-04-25 | 2006-11-02 | Yeda Research And Development Company | Markers associated with the therapeutic efficacy of glatiramer acetate |
| WO2007081975A2 (en) * | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US8378072B2 (en) | 2006-04-13 | 2013-02-19 | Declion Pharmaceuticals, Inc. | Methods for designing and synthesizing directed sequence polymer compositions via the directed expansion of epitope permeability |
| KR100831796B1 (ko) * | 2006-05-29 | 2008-05-28 | 엘지전자 주식회사 | 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법 |
| AU2007264682B2 (en) * | 2006-06-28 | 2012-09-06 | Yeda Research & Development Co. Ltd | Method of treatment of age-related macular degeneration |
| WO2009040814A1 (en) | 2007-09-24 | 2009-04-02 | Hadasit Medical Research Services & Development Ltd | Use of copolymer 1 for treatment of muscular dystrophy |
| AP3467A (en) | 2007-10-16 | 2015-11-30 | Peptimmune Inc | Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopes |
| CA2702437C (en) * | 2007-11-28 | 2013-06-25 | Teva Pharmaceutical Industries Ltd. | Method of delaying the onset of clinically definite multiple sclerosis |
| ES2449865T5 (es) | 2008-04-16 | 2022-11-18 | Momenta Pharmaceuticals Inc | Análisis de composiciones de copolímeros de aminoácidos |
| NZ598661A (en) | 2009-08-20 | 2013-02-22 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| HUE060304T2 (hu) | 2010-01-04 | 2023-02-28 | Mapi Pharma Ltd | Glatiramer acetátot tartalmazó depó rendszer |
| US8377885B2 (en) | 2010-01-04 | 2013-02-19 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| WO2011111043A1 (en) * | 2010-03-10 | 2011-09-15 | Yeda Research And Development Co. Ltd | Cellular blood markers for early diagnosis of als and for als progression |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| EP2412802A1 (en) * | 2010-07-29 | 2012-02-01 | TXCell | IL-13 producing TR1-like cells and use thereof |
| CA2814500A1 (en) | 2010-10-11 | 2012-04-19 | Teva Pharmaceutical Industries Ltd | Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate |
| WO2012143924A1 (en) | 2011-04-21 | 2012-10-26 | Mapi Pharma Ltd. | Random pentapolymer for treatment of autoimmune diseases |
| WO2013009885A2 (en) | 2011-07-11 | 2013-01-17 | Momenta Pharmaceuticals, Inc. | Evaluation of copolymer diethylamide |
| US8575198B1 (en) | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
| HK1200274A1 (en) | 2011-10-10 | 2015-08-07 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| WO2013144957A1 (en) * | 2012-03-26 | 2013-10-03 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression |
| WO2014037952A1 (en) | 2012-09-10 | 2014-03-13 | Yeda Research And Development Co. Ltd At The Weizmann Institute Of Science | Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia |
| JP6149831B2 (ja) * | 2014-09-04 | 2017-06-21 | 信越化学工業株式会社 | シリコーン組成物 |
| US20180303974A1 (en) | 2015-11-03 | 2018-10-25 | Ariel-University Research And Development Company Ltd. | Compositions for regeneration and repair of neural tissue |
| KR102425326B1 (ko) * | 2016-05-20 | 2022-07-25 | 세다르스-신나이 메디칼 센터 | 알츠하이머병 및 관련 병태의 치료 또는 예방 방법 |
| WO2018002930A1 (en) | 2016-06-30 | 2018-01-04 | Stem Cell Medicine Ltd. | Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| CN109982712A (zh) | 2016-08-31 | 2019-07-05 | Mapi医药公司 | 包含醋酸格拉替雷的储库系统 |
| CA3035561A1 (en) * | 2016-09-02 | 2018-03-08 | Christopher J. Soares | Use of cgrp receptor antagonists in neuroprotection and neurological disorders |
| CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
| EP3624815A4 (en) | 2017-05-15 | 2021-01-20 | Stem Cell Medicine Ltd. | TREATMENT OF MULTIPLE SCLEROSIS WITH LONG-ACTING GLATIRAMER AND ADAPTIVE STEM CELLS |
| EP3624816A4 (en) | 2017-05-15 | 2021-02-24 | Stem Cell Medicine Ltd. | TREATMENT OF MULTIPLE SCLEROSIS WITH STEM CELLS DERIVED FROM ADIPOUS TISSUE |
| CN114790475B (zh) * | 2021-01-25 | 2025-01-10 | 首都医科大学附属北京天坛医院 | 一种与亨廷顿病相关的肠道微生物及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) * | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| IL113812A (en) * | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| US6214791B1 (en) * | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| EP1054880A1 (en) * | 1998-02-13 | 2000-11-29 | Autoimmune, Inc. | TREATMENT OF MULTIPLE SCLEROSIS USING COP-1 AND Th2-ENHANCING CYTOKINES |
| JP4328050B2 (ja) * | 2000-01-20 | 2009-09-09 | イエダ リサーチ アンド デベロップメント カンパニー リミテッド | 神経保護療法のためのコポリマー１、関連ペプチド及びポリペプチドならびにそれらによって処理されたｔ細胞の使用 |
-
2001
- 2001-01-22 JP JP2001552925A patent/JP4328050B2/ja not_active Expired - Fee Related
- 2001-01-22 US US09/765,644 patent/US6844314B2/en not_active Expired - Lifetime
- 2001-01-22 PT PT01906631T patent/PT1248643E/pt unknown
- 2001-01-22 MX MXPA02007106A patent/MXPA02007106A/es active IP Right Grant
- 2001-01-22 IL IL15080001A patent/IL150800A0/xx active IP Right Grant
- 2001-01-22 DK DK01906631T patent/DK1248643T3/da active
- 2001-01-22 HK HK03106807.7A patent/HK1054507B/zh not_active IP Right Cessation
- 2001-01-22 AT AT01906631T patent/ATE302020T1/de active
- 2001-01-22 WO PCT/US2001/002117 patent/WO2001052878A2/en not_active Ceased
- 2001-01-22 CA CA002397785A patent/CA2397785C/en not_active Expired - Lifetime
- 2001-01-22 DE DE60112718T patent/DE60112718T2/de not_active Expired - Lifetime
- 2001-01-22 AU AU34517/01A patent/AU780188B2/en not_active Expired
- 2001-01-22 CN CNB01806602XA patent/CN100360180C/zh not_active Expired - Lifetime
- 2001-01-22 EP EP01906631A patent/EP1248643B1/en not_active Expired - Lifetime
- 2001-01-22 ES ES01906631T patent/ES2243450T3/es not_active Expired - Lifetime
- 2001-01-22 KR KR1020027009277A patent/KR100822695B1/ko not_active Expired - Lifetime
-
2002
- 2002-07-18 IL IL150800A patent/IL150800A/en unknown
-
2005
- 2005-01-13 US US11/034,262 patent/US7407936B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003520246A5 (enExample) | ||
| JP2004507460A5 (enExample) | ||
| CN100438906C (zh) | 共聚物1和相关肽和多肽及其处理过的t细胞在保护cns细胞避免谷氨酸毒性中的用途 | |
| CA2370289A1 (en) | Neuronal exocytosis inhibiting peptides and cosmetic and pharmaceutical compositions containing said peptides | |
| US20120135016A1 (en) | Induction of neurogenesis and stem cell therapy in combination with copolymer 1 | |
| JP2006506942A5 (enExample) | ||
| WO1999060021A3 (en) | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system | |
| DK1248643T3 (da) | Anvendelse af copolymer 1 og beslægtede peptider og polypeptider og T-celler behandlet dermed til neurobeskyttende terapi | |
| JP2003518507A5 (enExample) | ||
| RU2000131593A (ru) | Селективные агонисты и антагонисты il-2. | |
| RU2013112616A (ru) | Пептид cdca1 и включающее его фармацевтическое средство | |
| JP2008530975A5 (enExample) | ||
| CA2411786A1 (en) | A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids | |
| WO2000075173A3 (en) | Peptide fragments of colostrinin | |
| CY1112867T1 (el) | Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια | |
| JP2009542622A5 (enExample) | ||
| RU2009129531A (ru) | Вакцины на основе пептида foxp3 | |
| WO2003105750A3 (en) | ANTIGEN PRESENTER CELLS FOR NEUROPROTECTION AND NERVOUS REGENERATION | |
| JPH0618777B2 (ja) | 精神神経性欠損症の治療に用いられる組成物 | |
| RU2007115411A (ru) | Пептиды hsp60 и их apl-производные и фармацевтические композиции | |
| RU2012100241A (ru) | Лечение хориоидальной неоваскуляризации с помощью вакцин | |
| WO2006072946A3 (en) | Hsp60, hsp60 peptides and t cell vaccines for immunomodulation | |
| ES2732669T3 (es) | Tratamiento de la esclerosis múltiple | |
| Arnon et al. | Suppression of demyelinating diseases by synthetic copolymers | |
| WO1998042746A3 (en) | Synthetic saposin c-derived neurotrophic peptides |